Fulfilling the promise of cell & gene therapies through manufacturing (Part I)
The Top Line
Revamping Supply Chains and Accelerating Cell Therapy Reach
Exploring the speaker's journey in developing single-dose curative treatments, the chapter emphasizes the creation of an internal biotech group within MD Anderson Cancer Center to optimize processes and facilitate the translation of products from research to clinical phases. Through collaborations with companies like Obsidian Therapeutics and successful clinical outcomes, the importance of partnerships in expediting the availability of cell therapies to patients is underscored.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
